Back

Early respiratory–metabolic phenotypes predict 48-hour hemodynamic deterioration in intermediate-high risk pulmonary embolism

29 August 2026 (08:51 - 09:03)
Organised by: Logo
Congress Presentation Part of: Acute pulmonary embolism: risk and interventional therapies Epidemiology, Prognosis, Outcome ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Marco Zuin

University of Ferrara, Ferrara (Italy)

4 More presentations in this session

Presentation thumbnail
Activated factor XI is associated with recurrent venous thromboembolism in patients following pulmonary embolism: a cohort study
Mr P. Michel (Krakow, PL)
Abstract Slides
Presentation thumbnail
High-risk pe patients eligible for both large-bore mechanical thrombectomy and systemic thrombolysis: insights from the FLASH and FLAME Studies
Doctor L. Hobohm (Mainz, DE)
Abstract Slides
Presentation thumbnail
Patients with pulmonary embolism and cardiogenic shock benefit from interventional therapy rather than conventional thrombolytic therapy. A case analysis of all inpatients in Germany 2022 and 2025
Doctor S. Lange (Munster, DE)
Abstract Slides
Presentation thumbnail
Catheter-directed therapy in intermediate-high risk pulmonary embolism: which predictive factors for a favorable therapy response?
Doctor E. Blachere (Montpellier, FR)
Abstract Slides

Access the full session

Session thumbnail
Acute pulmonary embolism: risk and interventional therapies
Video

The Event

Event poster

ESC Congress 2026

29 August 2026 08:51 CET
You may be interested in
thumbnail
Congress Presentation
TELOS-plus identifies normotensive patients with pulmonary embolism at high risk (>10%) of 30-day mortality
1 September 2025
thumbnail
Congress Presentation
Selecting the right patient at the right time: predictors and early decision-making in acute pulmonary embolism
20 March 2026
thumbnail
Congress Presentation
Parameters for better stratifying intermediate-high risk patients affected by acute pulmonary embolism
1 September 2025
thumbnail
Congress Presentation
Adding clinical markers of more severe form of intermediate-high risk pulmonary embolism improves risk stratification and possibly identifies candidates for fibrinolytic therapy
19 March 2022

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources